The effect of ML264 (Klf5 inhibitor) on aneurysm formation induced by Ang II infusion in the early and late stages. by Dong Ma (584680)

Subjects:

Cardiac function assessed by echocardiography in Ang II–infused young (3 months) or old (18 months) WT and smcKlf5^−/− mice. by Dong Ma (584680)

Subjects:

Klf5 deficiency leads to mitochondrial dyfunction in VSMCs. by Dong Ma (584680)

Subjects:

Klf5 deficiency in mouse VSMCs leads to mitochondrial fission. by Dong Ma (584680)

Subjects:

ATP assay. by Dong Ma (584680)

Subjects:

Representative TUNEL- and DAPI-stained sections from the abdominal aortas of young and old WT and smcKlf5^−/− mice following 28 days of Ang II infusion. by Dong Ma (584680)

Subjects:

eIF5a affects the expression of mitochondrial dynamics–related genes. by Dong Ma (584680)

Subjects:

Young (3 months) or old (18 months) WT and smcKlf5^−/− mice were infused with Ang II for 28 days. by Dong Ma (584680)

Subjects:

Klf5 down-regulation leads to human VSMC senescence. by Dong Ma (584680)

Subjects:

The spectral sensitivity of European seabass fed a 5% taurine diet. by Richard W. Brill (2337940)

Decreased Sho levels in ScN2a-Sho cells. by Joel C. Watts (195735)

“…(<b>C</b>) Quantification of Sho levels in ScN2a-Sho-1 (<i>n</i> = 10) and ScN2a-Sho-2 (<i>n</i> = 5) subclones revealed a significant decrease of 40–45% compared to the uninfected parental cell line (<i>n</i> = 15) (***<i>P</i><0.001).…”

Change of oxygen concentration at each measuring point. by Yun Qi (560401)

Decreased 5-Hydroxymethylcytosine Is Associated with Neural Progenitor Phenotype in Normal Brain and Shorter Survival in Malignant Glioma by Brent A. Orr (150119)

FUD transiently decreased IOP in mice injected with Ad5-TGFβ2 viral vector. by Jennifer A. Faralli (4907311)

“…(B) IOPs were monitored for 5 more days (until Day 22) in a subset of mice from A. …”

Cullin-1/5 degradation requires Gal-lectin-mediated contact with macrophage. by Attinder Chadha (11414273)

Subjects:

Identification of small molecules that inhibit viral M mRNA nuclear export and/or decrease viral M mRNA levels. by Matthew Esparza (8661219)

“…To better visualize the distribution of compounds within the desired range (Z-score < -3), the Z-score range of the graph has been focused to view data points that show decrease in viral M mRNA fluorescence.…”

Data extraction grid. by Heloisa Ricci Conesa (18291210)

“…No homogenous trends were identified in incidence rates across countries, or in detection of S. pneumoniae as a cause of AOM over time. There were indications of a reduction in hospitalization rates (decreases between 24.5–38.8% points, depending on country, PCV type and time since PCV introduction) and antibiotic resistance (decreases between 14–24%, depending on country), following the widespread use of PCVs over time. …”

Incidence rates of AOM cases. by Heloisa Ricci Conesa (18291210)

“…No homogenous trends were identified in incidence rates across countries, or in detection of S. pneumoniae as a cause of AOM over time. There were indications of a reduction in hospitalization rates (decreases between 24.5–38.8% points, depending on country, PCV type and time since PCV introduction) and antibiotic resistance (decreases between 14–24%, depending on country), following the widespread use of PCVs over time. …”

Inclusion criteria. by Heloisa Ricci Conesa (18291210)

“…No homogenous trends were identified in incidence rates across countries, or in detection of S. pneumoniae as a cause of AOM over time. There were indications of a reduction in hospitalization rates (decreases between 24.5–38.8% points, depending on country, PCV type and time since PCV introduction) and antibiotic resistance (decreases between 14–24%, depending on country), following the widespread use of PCVs over time. …”

PRISMA flow diagram for the literature search. by Heloisa Ricci Conesa (18291210)

“…No homogenous trends were identified in incidence rates across countries, or in detection of S. pneumoniae as a cause of AOM over time. There were indications of a reduction in hospitalization rates (decreases between 24.5–38.8% points, depending on country, PCV type and time since PCV introduction) and antibiotic resistance (decreases between 14–24%, depending on country), following the widespread use of PCVs over time. …”